AAK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL203803	0.52	8/20
SCHEMBL90567	0.51	7/20
SCHEMBL64834	0.53	5/20
SCHEMBL57148	0.47	5/20
SCHEMBL90111	0.47	5/20
SCHEMBL197145	0.46	5/20
SCHEMBL182885	0.45	5/20
SCHEMBL81403	0.36	5/20
SCHEMBL68681	0.33	5/20
SCHEMBL197036	0.53	4/20
SCHEMBL61963	0.53	4/20
SCHEMBL56753	0.47	4/20
SCHEMBL56754	0.47	4/20
SCHEMBL205627	0.42	4/20
SCHEMBL143512	0.52	3/20
SCHEMBL144435	0.51	3/20
SCHEMBL147381	0.50	3/20
SCHEMBL147709	0.50	3/20
SCHEMBL147544	0.47	3/20
SCHEMBL149883	0.47	3/20

Clinical trials — most relevant to AAK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)	PHASE4	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Feasibility of Metformin for Sepsis Induced AKI	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity	PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Effect of Metformin on Chronic Pain After Thoracic Surgery in Diabetic Patients	nan	UNKNOWN
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Normal Serum Adiponectin Levels in Females	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a AAK1 binder may also engage these)

Protein	Name	Similarity
P0C1X8	—	1.000	P0C1X8 →
Q3UHJ0	—	1.000	Q3UHJ0 →
F1SPM8	—	1.000	F1SPM8 →
F1MH24	—	1.000	F1MH24 →
Q2EJA0	—	0.996	Q2EJA0 →
Q91Z96	—	0.995	Q91Z96 →
Q2LC84	—	0.995	Q2LC84 →
Q9ULH7	—	0.994	Q9ULH7 →
Q64332	—	0.994	Q64332 →
Q8K0V4	—	0.994	Q8K0V4 →
Q62901	—	0.994	Q62901 →
Q8CHU3	—	0.994	Q8CHU3 →
P98082	—	0.993	P98082 →
A0A8C0NGY6	—	0.993	A0A8C0NGY6 →
O70441	—	0.993	O70441 →
Q6P4S6	—	0.993	Q6P4S6 →
P34333	—	0.993	P34333 →
Q9UPN6	—	0.993	Q9UPN6 →
Q7TN99	—	0.993	Q7TN99 →
Q86TC9	—	0.993	Q86TC9 →
Q9QZS3	—	0.993	Q9QZS3 →
CHD8	Chromodomain-helicase-DNA-binding protein 8	0.993	landscape →
Q6NZJ6	—	0.993	Q6NZJ6 →
Q6NSM8	—	0.993	Q6NSM8 →
Q498D1	—	0.993	Q498D1 →
SIK3	Serine/threonine-protein kinase SIK3	0.993	landscape →
Q4VYS1	—	0.992	Q4VYS1 →
Q80TN7	—	0.992	Q80TN7 →
Q63627	—	0.992	Q63627 →
P23899	—	0.992	P23899 →